Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
Portfolio Pulse from
Optimi Health Corp. has entered into agreements to supply GMP-certified psilocybin for Psyence Biomed's Phase IIb palliative care trial, with potential for future Phase III trials.
December 17, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Optimi Health will supply GMP-certified psilocybin for Psyence Biomed's clinical trials, potentially boosting its market presence in the palliative care sector.
The agreement to supply psilocybin for clinical trials positions Optimi Health as a key player in the palliative care market, likely increasing demand for its products.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Psyence Biomed will use Optimi Health's psilocybin in its Phase IIb and future Phase III palliative care trials, potentially advancing its clinical research and market position.
The use of Optimi's psilocybin in trials could enhance Psyence Biomed's research capabilities and market credibility in palliative care solutions.
CONFIDENCE 85
IMPORTANCE 65
RELEVANCE 70